Sacubitril + Valsartan

[MAF] Sacubitril & Valsartan Tablet, Sacubitril 24 mg + Valsartan 26 mg, Sacubitril 49 mg + Valsartan 51 mg, Sacubitril 97 mg + Valsartan 103 mg

1. To reduce the risk of cardiovascular death and hospitalisation for heart failure (HF) in patients:
   • with chronic HF classified by NYHA Class II-IV symptoms; and
   • with left ventricular ejection fraction of 40% or less; and
   • who are receiving concomitant optimal standard chronic heart failure treatment, which includes a beta-blocker, unless contraindicated or not tolerated; and
   • who remain symptomatic despite already receiving a stable dose of an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment is contraindicated or cannot be tolerated.

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

04/01/2022 Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction

The Ministry of Health’s Drug Advisory Committee has recommended:

• Sacubitril/valsartan 50 mg, 100 mg and 200 mg tablets to reduce the risk of cardiovascular death and hospitalisation for heart failure in patients:

  • with chronic heart failure classified by New York Heart Association (NYHA) Class II - IV symptoms; and

  • with left ventricular ejection fraction of 40% or less; and

  • who are receiving concomitant optimal standard chronic heart failure treatment, which includes a beta-blocker, unless contraindicated or not tolerated; and

  • who remain symptomatic despite already receiving a stable dose of an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin II receptor blocker (ARB), unless such treatment is contraindicated or cannot be tolerated.

Sacubitril/valsartan must not be co-administered with an ACE inhibitor or an ARB.

Subsidy status

[R] Sacubitril/valsartan 50 mg, 100 mg and 200 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration